Which regulatory pathway is commonly used for new orthopedic devices in the United States?

• A. 510(k) clearance for devices substantially equivalent to a predicate
• B. Premarket Approval (PMA) for high-risk devices
• C. De Novo pathway
• D. Investigational Device Exemption (IDE)

Answer: (A)

In the United States, orthopedic devices commonly enter the market by showing that the new device is substantially equivalent to a legally marketed predicate device. This is the 510(k) clearance pathway. The idea is that if the new device has the same intended use and similar technological characteristics as an existing, approved device, it can be cleared with less data than a full premarket approval. The focus is on demonstrating no new safety or effectiveness concerns compared to the predicate, often with bench testing, biocompatibility data, and some clinical information as needed. This route is faster and less burdensome than PMA, which is reserved for high-risk devices. If there’s no predicate because the device introduces a truly new technology, De Novo can be used to establish a new classification and create a new predicate for future devices, but that’s less common for standard orthopedic implants. Investigational Device Exemption, meanwhile, is not a market path—it allows clinical studies to be conducted but does not itself grant clearance to market the device.